Company Shares of Myriad Genetics (NASDAQ:MYGN) Rally 2.99%

Myriad Genetics (NASDAQ:MYGN) : Traders are bullish on Myriad Genetics (NASDAQ:MYGN) as it has outperformed the S&P 500 by a wide margin of 0.76% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.69%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.99% in the last 1 week, and is up 2.39% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The company shares have dropped -5.18% from its 1 Year high price. On Nov 4, 2015, the shares registered one year high at $46.24 and the one year low was seen on Jun 24, 2016. The 50-Day Moving Average price is $32.14 and the 200 Day Moving Average price is recorded at $36.36.

The stock has recorded a 20-day Moving Average of 3.26% and the 50-Day Moving Average is 4.53%.


Myriad Genetics (NASDAQ:MYGN): stock turned positive on Friday. Though the stock opened at $30.98, the bulls momentum made the stock top out at $31.77 level for the day. The stock recorded a low of $30.92 and closed the trading day at $31.69, in the green by 2.62%. The total traded volume for the day was 1,717,453. The stock had closed at $30.88 in the previous days trading.

In an insider trading activity, The officer (President, MGL), of Myriad Genetics Inc, Ford Alexander had unloaded 18,637 shares at $30.87 per share in a transaction on June 21, 2016. The total value of transaction was $575,324. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing, or assess a patients risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.